Amyloidosis – pipeline review, h2 2012


Published on

Aarkstore Enterprise-Amyloidosis – pipeline review, h2 2012

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Amyloidosis – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Amyloidosis – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Amyloidosis - Pipeline Review, H2 2012, provides anoverview of the indication’s therapeutic pipeline. This report provides informationon the therapeutic development for Amyloidosis, complete with latest updates, andspecial features on late-stage and discontinued projects. It also reviews key playersinvolved in the therapeutic development for Amyloidosis. Amyloidosis - PipelineReview, Half Year is built using data and information sourced from Global MarketsDirect’s proprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Amyloidosis.- A review of the Amyloidosis products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.
  2. 2. Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Amyloidosis.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 8List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Amyloidosis Overview 11Therapeutics Development 12An Overview of Pipeline Products for Amyloidosis 12Amyloidosis Therapeutics under Development by Companies 14Amyloidosis Therapeutics under Investigation by Universities/Institutes 16Late Stage Products 19Comparative Analysis 19Mid Clinical Stage Products 20Comparative Analysis 20Early Clinical Stage Products 21Comparative Analysis 21Discovery and Pre-Clinical Stage Products 22Comparative Analysis 22Amyloidosis Therapeutics – Products under Development by Companies 23Amyloidosis Therapeutics – Products under Investigation by Universities/Institutes24Companies Involved in Amyloidosis Therapeutics Development 26GlaxoSmithKline plc 26Isis Pharmaceuticals, Inc. 27Millennium Pharmaceuticals, Inc. 28Elan Corporation, plc 29Pfizer Inc. 30Alnylam Pharmaceuticals, Inc 31
  3. 3. ProteoTech, Inc. 32BIOALVO S.A. 33List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1Neutropenia – Pipeline Review, H2 2012Amyloidosis – Pipeline Review, H2 2012Human Papillomavirus Infections – Pipeline Review, H2 2012Cancer Pain – Pipeline Review, H2 2012Dengue – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,
  4. 4. H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: